[Pediatric Intracranial Ependymoma - Recommendations for First-Line Treatment from the German HIT-MED study group].

Abstract

Biological subtypes of ependymoma (EPN) have been introduced by the recent WHO classification and appear to have great impact on the clinical course, but have not yet found their way into clinical risk stratification. Further, the overall unfavorable prognosis underlines the fact that current therapeutic strategies need further evaluation for improvement. To date, there is no international consensus regarding first-line treatment for children with intracranial EPN. Extent of resection is known to be the most important clinical risk factor, leading to the consensus that consequent evaluation for re-surgery of postoperative residual tumor needs to have highest priority. Furthermore, efficacy of local irradiation is unquestioned and recommended for patients aged>1 year. In contrast, efficacy of chemotherapy is still under discussion. The European trial SIOP Ependymoma II aims at evaluating efficacy of different chemotherapy elements, leading to the recommendation to include German patients. The BIOMECA study, as biological accompanying study, aims at identifying new prognostic parameters. These results might help to develop targeted therapies for unfavorable biological subtypes. For patient who are not qualified for inclusion into the interventional strata, the HIT-MED Guidance 5.2 provides specific recommendations. This article is meant as an overview of national guidelines regarding diagnostics and treatment as well as of treatment according to the SIOP Ependymoma II trial protocol.

• Authors: Denise Obrecht, Martin Mynarek, Martina Stickan-Verfürth, Brigitte Bison, Ulrich Schüller, Kristian Pajtler, Christian Hagel, Ulrich-Wilhelm Thomale, Gudrun Fleischhack, Beate Timmermann, Stefan Rutkowski
• Journal: Klinische Padiatrie (Klin Padiatr) Vol. 235 Issue 3 Pg. 167-177 (May 2023) ISSN: 1439-3824 [Electronic] Germany
• Vernacular Title: Kinder und Jugendliche mit intrakraniellem Ependymom – Empfehlungen der HIT-MED-Studiengruppe der GPOH zur Erstlinientherapie.
• PMID: 37172610 (Publication Type: English Abstract, Journal Article)
• Copyright: Thieme. All rights reserved.

Topics

• Child
• Humans
• Brain Neoplasms (drug therapy, pathology)
• Prognosis
• Combined Modality Therapy
• Risk Factors
• Ependymoma (diagnosis, therapy, pathology)